VEGFXTA 400MG INJ VIAL

About

Bevacizumab is a highly specific recombinant humanized monoclonal antibody that functions as an anti-angiogenic agent by selectively binding to and neutralizing vascular endothelial growth factor A (VEGF-A). By sequestering VEGF-A, bevacizumab effectively inhibits the formation of new blood vessels (angiogenesis) that are essential for tumor growth, survival, and metastasis. This deprivation of blood supply, oxygen, and nutrients leads to the regression of existing tumor vasculature and prevents the development of new ones, thereby impeding tumor proliferation. It is widely utilized in combination with various chemotherapy regimens for the treatment of several advanced or metastatic solid tumors, significantly improving progression-free and overall survival by disrupting the tumor's microenvironment.

Uses

• Metastatic colorectal cancer
• Non-small cell lung cancer
• Glioblastoma
• Metastatic renal cell carcinoma

Directions For Use

Administered intravenously by a healthcare professional. Dosage and frequency are determined by the physician based on the specific cancer and patient's weight.

Benefits

• Inhibits tumor angiogenesis.
• Effective in various advanced solid tumors.
• Improves progression-free survival and overall survival.
• Used in combination with chemotherapy for enhanced efficacy.
• Targets a key pathway in cancer growth.
• Reduces tumor size and spread.

Side Effects

• Hypertension (high blood pressure)
• Proteinuria
• Thromboembolic events (blood clots)
• Hemorrhage (bleeding)
• Gastrointestinal perforation
• Wound healing complications
• Fatigue
• Headache
• Diarrhea
• Nasal septum perforation
• Reversible posterior leukoencephalopathy syndrome (RPLS)
• Infusion-related reactions

Safety Measures

• Alcohol - No specific contraindication, but general avoidance during cancer treatment is often advised to minimize overall systemic burden.
• Pregnancy - Bevacizumab is embryotoxic and teratogenic. It is contraindicated in pregnancy; effective contraception is essential during treatment and for at least 6 months after the last dose.
• Breastfeeding - Breastfeeding is contraindicated during bevacizumab therapy and for at least 6 months after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; monitor liver function tests. No specific dose adjustment guidelines, but clinical judgment is required.
• Kidney - Use with caution in patients with renal impairment; monitor kidney function tests and proteinuria. No specific dose adjustment guidelines.
• Lung - Rare cases of pulmonary hemorrhage and fistula formation have been reported, particularly in lung cancer patients. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.